Langerhans Cells and T Cells Sense Cell Dysplasia in Oral Leukoplakias and Oral Squamous Cell Carcinomas - Evidence for Immunosurveillance

Scandinavian Journal of Immunology

Volumn 76, Issue 1, 2012, Pages 39-48

  Ohman J ^a,b   Magnusson, B ^a,c   Telemo, E ^d   Jontell, M ^a   Hasseus B ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Public Dental Service   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; KI 67 ANTIGEN; LANGERIN;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; CONNECTIVE TISSUE; DENDRITIC CELL; DYSPLASIA; EPITHELIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; LANGERHANS CELL; LASER SCANNING CYTOMETRY; LEUKOPLAKIA; MALE; ORAL BIOPSY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; LANGERHANS CELLS; LEUKOPLAKIA, ORAL; MICROSCOPY, CONFOCAL; MIDDLE AGED; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES;

EID: 84862247716     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02701.x     Document Type: Article

References (52)

1. Mithani SK, Mydlarz WK, Grumbine FL, Smith IM, Califano JA. Molecular genetics of premalignant oral lesions. Oral Dis 2007;13:126-33.
2. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984;53:563-8.
3. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006;42:461-74.
4. Brennan M, Migliorati CA, Lockhart PB et al. Management of oral epithelial dysplasia: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103 (SUPPL):S19-e1.
5. Van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 2009;45:317-23.
6. Noone RB, Bonner H Jr, Raymond S, Brown AS, Graham WP 3rd, Lehr HB. Lymph node metastases in oral carcinoma. A correlation of histopathology with survival. Plast Reconstr Surg 1974;53:158-66.
7. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-27.
8. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
9. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
10. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
11. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
12. Kalinski P, Okada H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol 2010;22:173-82.
13. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
14. Falo LD Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1995;1:649-53.
15. Matheoud D, Perie L, Hoeffel G et al. Cross-presentation by dendritic cells from live cells induces protective immune responses in vivo. Blood 2010;115:4412-20.
16. Von Euw EM, Barrio MM, Furman D et al. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med 2007;5:19.
17. Shaif-Muthana M, McIntyre C, Sisley K, Rennie I, Murray A. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res 2000;60:6441-7.
18. Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL, Furuya N. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2006;55:151-9.
19. Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
20. Ladanyi A, Kiss J, Somlai B et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007;56:1459-69.
21. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
22. Taheri-Kadkhoda Z, Magnusson B, Svensson M, Mercke C, Bjork-Eriksson T. Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck 2009;31:482-92.
23. Klein O, Ebert LM, Nicholaou T et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009;15:2507-13.
24. Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 1999;190:125-33.
25. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-34.
26. Savina A, Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunol Rev 2007;219:143-56.
27. Karbach J, Gnjatic S, Pauligk C et al. Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. Int J Cancer 2007;121:2042-8.
28. Janicki CN, Jenkinson SR, Williams NA, Morgan DJ. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res 2008;68:2993-3000.
29. Iwamoto M, Shinohara H, Miyamoto A et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003;104:92-7.
30. Treilleux I, Blay JY, Bendriss-Vermare N et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004;10:7466-74.
31. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993;25:338-43.
32. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001;91:2136-47.
33. Pitigala-Arachchi A, Crane IJ, Scully C, Prime SS. Epithelial dendritic cells in pathological human oral tissues. J Oral Pathol Med 1989;18:11-16.
34. Abiko Y, Jinbu Y, Noguchi T et al. Upregulation of human beta-defensin 2 peptide expression in oral lichen planus, leukoplakia and candidiasis. an immunohistochemical study. Pathol Res Pract 2002;198:537-42.
35. Gustafson J, Eklund C, Wallstrom M, Zellin G, Magnusson B, Hasseus B. Langerin-expressing and CD83-expressing cells in oral lichen planus lesions. Acta Odontol Scand 2007;65:156-61.
36. Syafriadi M, Cheng J, Jen KY, Ida-Yonemochi H, Suzuki M, Saku T. Two-phase appearance of oral epithelial dysplasia resulting from focal proliferation of parabasal cells and apoptosis of prickle cells. J Oral Pathol Med 2005;34:140-9.
37. Gannot G, Gannot I, Vered H, Buchner A, Keisari Y. Increase in immune cell infiltration with progression of oral epithelium from hyperkeratosis to dysplasia and carcinoma. Br J Cancer 2002;86:1444-8.
38. Zancope E, Costa NL, Junqueira-Kipnis AP et al. Differential infiltration of CD8(+) and NK cells in lip and oral cavity squamous cell carcinoma. J Oral Pathol Med 2009;39:162-7.
39. Gibbings D, Befus AD. CD4 and CD8: an inside-out coreceptor model for innate immune cells. J Leukoc Biol 2009;86:251-9.
40. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010;1183:89-103.
41. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res 2003;9:4296-303.
42. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004;84:131-79.
43. Valladeau J, Ravel O, Dezutter-Dambuyant C et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000;12:71-81.
44. Valladeau J, Dezutter-Dambuyant C, Saeland S. Langerin/CD207 sheds light on formation of birbeck granules and their possible function in Langerhans cells. Immunol Res 2003;28:93-107.
45. Wischatta M, Brunhuber T, Neher A et al. Phenotypic characterization and distribution of dendritic cells in parotid gland tumors. ORL J Otorhinolaryngol Relat Spec 2004;66:313-19.
46. Suzuki H, Chikazawa N, Tasaka T et al. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 2009;59:653-61.
47. Hasseus B, Jontell M, Brune M, Johansson P, Dahlgren UI. Langerhans cells and T cells in oral graft versus host disease and oral lichen planus. Scand J Immunol 2001;54:516-24.
48. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
49. Pich A, Chiusa L, Navone R. Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol 2004;15:1319-29.
50. Vered M, Allon I, Dayan D. Maspin, p53, p63, and Ki-67 in epithelial lesions of the tongue: from hyperplasia through dysplasia to carcinoma. J Oral Pathol Med 2009;38:314-20.
51. Torres-Rendon A, Roy S, Craig GT, Speight PM. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer 2009;100:1128-34.
52. Karlsson M, Lindberg K, Karlen P et al. Evidence for immunosurveillance in intestinal premalignant lesions. Scand J Immunol 2010;71:362-8.